Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Amgen, Novartis, Banner Institute Discontinue Alzheimer's Prevention Clinical Research Program

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2019 | 05:16pm EDT

By Stephen Nakrosis

Amgen Inc. said Thursday a clinical research program it was conducting into Alzheimer's prevention with Novartis AG (NVS) and the Banner Alzheimer's Institute was being discontinued.

The program was studying the effect of the BACE1 inhibitor CNP520, or umibecestat, as part of the Alzheimer's Prevention Initiative Generation Program, Amgen said. Specifically, the program was researching the safety and efficacy of CNP520 for the prevention or delay of the onset of Alzheimer's disease in certain patients.

Amgen said "After review of clinical data, the sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk."

Amgen and Novartis formed a global collaboration in 2015 to develop and commercialize pioneering treatments in the field of migraine and Alzheimer's disease. The studies are sponsored by Amgen and Novartis, in collaboration with Banner Alzheimer's Institute, Amgen said.

David Reese, executive vice president of Research and Development at Amgen, said "Although the outcomes of the research program did not lead to the results we aimed for, we are committed to sharing our findings to help advance the medical and scientific community one step further toward finding a prevention for this devastating disease."

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
AMGEN -1.40% 175.89 Delayed Quote.-8.36%
NOVARTIS -0.22% 92.5 Delayed Quote.24.78%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
10:14aNOVARTIS : key multiple sclerosis Product Gilenya approved in China
AQ
01:16aNOVARTIS : Sandoz announces first patient enrolled in clinical study for propose..
GL
07/19ALCON : Novartis delivers strong sales, double digit core operating income growt..
AQ
07/19Gilead Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
DJ
07/19NOVARTIS : key multiple sclerosis product Gilenya® approved in China
PU
07/18EUROPE : ECB report eases earnings pain for European stocks
RE
07/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/18GLOBAL MARKETS LIVE : Microsoft, Qualcomm, Netflix, Facebook…
07/18NEWS HIGHLIGHTS : Top Company News of the Day
DJ
07/18Weak Earnings, Trade Tensions Weigh on Global Stocks
DJ
More news
Financials (USD)
Sales 2019 46 888 M
EBIT 2019 13 811 M
Net income 2019 10 249 M
Debt 2019 17 311 M
Yield 2019 3,21%
P/E ratio 2019 24,7x
P/E ratio 2020 21,8x
EV / Sales2019 4,89x
EV / Sales2020 4,56x
Capitalization 212 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 93,30  $
Last Close Price 92,50  $
Spread / Highest target 16,2%
Spread / Average Target 0,87%
Spread / Lowest Target -17,3%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS24.78%216 273
JOHNSON & JOHNSON0.98%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
MERCK AND COMPANY6.52%209 550